Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population

Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population

Abstract We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a cl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Forum Infectious Diseases 2019-02, Vol.6 (2), p.ofz028-ofz028
Hauptverfasser: Bryson-Cahn, Chloe, Beieler, Alison M, Chan, Jeannie D, Harrington, Robert D, Dhanireddy, Shireesha
Format: Artikel
Sprache:eng
Schlagworte:
Brief Report
Care and treatment
Dalbavancin
Diseases
Endocarditis
Health aspects
Methicillin
Staphylococcus aureus
Staphylococcus aureus infections
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical response to treatment. Only 1 patient who completed the intended dalbavancin course experienced a treatment failure.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofz028